Regeneron Pharmaceuticals, Inc.'s stock continues to remain in the accumulation phase even after the setbacks associated primarily with itepekimab and Eylea. At the same time, Dupixent will remain Regeneron's key "cash cow" and its savior, the profit from sales of which will rise sharply in 2027. From its oncology franchise, I highlight Lynozyfic, which received its first FDA approval on July 2, and Libtayo, whose sales reached $285 million in Q1 2025.
REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.
The U.S. Food and Drug Administration has approved Regeneron's cancer therapy, the company said on Wednesday, providing another treatment option for patients with a recurring and common form of blood cancer.
30 Jul 2025 (In 2 weeks) Date | | 8.53 Cons. EPS | - EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | 11.38 Cons. EPS | 12.07 EPS |
31 Oct 2024 Date | | 11.69 Cons. EPS | 12.46 EPS |
1 Aug 2024 Date | | 10.61 Cons. EPS | 11.56 EPS |
30 Jul 2025 (In 2 weeks) Date | | 8.53 Cons. EPS | - EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | 11.38 Cons. EPS | 12.07 EPS |
31 Oct 2024 Date | | 11.69 Cons. EPS | 12.46 EPS |
1 Aug 2024 Date | | 10.61 Cons. EPS | 11.56 EPS |
Biotechnology Industry | Healthcare Sector | Leonard S. Schleifer CEO | NASDAQ (NGS) Exchange | 75886F107 Cusip |
US Country | 15,158 Employees | - Last Dividend | - Last Split | 2 Apr 1991 IPO Date |
Regeneron Pharmaceuticals, Inc. is a biotechnology firm that is renowned for its dedication to discovering, inventing, developing, manufacturing, and commercializing medicines to combat a variety of diseases globally. Since its inception in 1988, the company has been at the forefront of innovative treatments, striving to address the unmet medical needs of patients around the world. With its headquarters nested in Tarrytown, New York, Regeneron has made a significant impact in the pharmaceutical industry by delivering life-changing medicines to patients in need.
Regeneron Pharmaceuticals, Inc. offers a diverse portfolio of products aimed at treating a wide range of diseases, including but not limited to, eye diseases, allergies and inflammations, cardiovascular and metabolic conditions, infectious diseases, rare diseases, cancers, pain, and hematologic conditions.
In addition to these products, Regeneron is continuously working on developing new treatments for a variety of diseases, demonstrating their commitment to innovation and improving patient health worldwide.